These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23468226)

  • 21. Intraoperative use of low-dose recombinant activated factor VII during thoracic aortic operations.
    Andersen ND; Bhattacharya SD; Williams JB; Fosbol EL; Lockhart EL; Patel MB; Gaca JG; Welsby IJ; Hughes GC
    Ann Thorac Surg; 2012 Jun; 93(6):1921-8; discussion 1928-9. PubMed ID: 22551846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant factor VIIa: decreasing time to intervention in coagulopathic patients with severe traumatic brain injury.
    Stein DM; Dutton RP; Kramer ME; Handley C; Scalea TM
    J Trauma; 2008 Mar; 64(3):620-7; discussion 627-8. PubMed ID: 18332801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant human coagulation factor VIIa in Jehovah's Witness patients undergoing liver transplantation.
    Jabbour N; Gagandeep S; Peilin AC; Boland B; Mateo R; Genyk Y; Selby R; Zeger G
    Am Surg; 2005 Feb; 71(2):175-9. PubMed ID: 16022020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Administration of recombinant activated factor VII in the intensive care unit after complex cardiovascular surgery: clinical and economic outcomes.
    Uber WE; Toole JM; Stroud MR; Haney JS; Lazarchick J; Crawford FA; Ikonomidis JS
    J Thorac Cardiovasc Surg; 2011 Jun; 141(6):1469-77.e2. PubMed ID: 21457998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characteristics Associated With Mortality in 372 Patients Receiving Low-Dose Recombinant Factor VIIa (rFVIIa) for Cardiac Surgical Bleeding.
    Baral P; Cotter E; Gao G; He J; Wirtz K; Sharma A; Zorn Iii T; Muehlebach G; Flynn B
    J Cardiothorac Vasc Anesth; 2019 Aug; 33(8):2133-2140. PubMed ID: 30772178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intraoperative use of recombinant activated factor VII during complex aortic surgery.
    Goksedef D; Panagopoulos G; Nassiri N; Levine RL; Hountis PG; Plestis KA
    J Thorac Cardiovasc Surg; 2012 May; 143(5):1198-204. PubMed ID: 22285329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Recombinant Factor VII as Rescue for Severe Perioperative Bleeding in HeartMate II Recipients.
    Karimi A; Daigle SS; Smith WB; Janelle GM; Klodell CT
    J Card Surg; 2015 Jun; 30(6):500-5. PubMed ID: 25939953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant activated factor VII use in critically ill patients: clinical outcomes and thromboembolic events.
    Brophy GM; Candeloro CL; Robles JR; Brophy DF
    Ann Pharmacother; 2013 Apr; 47(4):447-54. PubMed ID: 23535812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preemptive administration of recombinant factor VII (rVIIa) in patients transplanted due to fulminant Wilson's disease.
    Czuprynska MM; Wawrzynowicz-Syczewska M; Jureczko L; Andrzejewska J; Jarosz K; Trzebicki J; Pacholczyk M; Chmura A; Wojcicki M
    Ann Transplant; 2010; 15(3):7-10. PubMed ID: 20877260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of recombinant factor VIIa in US military casualties for a five-year period.
    Wade CE; Eastridge BJ; Jones JA; West SA; Spinella PC; Perkins JG; Dubick MA; Blackbourne LH; Holcomb JB
    J Trauma; 2010 Aug; 69(2):353-9. PubMed ID: 20699744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of using recombinant activated factor VII as an off-label rescue treatment for critical bleeding requiring massive transfusion.
    Ho KM; Litton E
    Transfusion; 2012 Aug; 52(8):1696-702. PubMed ID: 22211634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries.
    Bonnet PO; Yoon BS; Wong WY; Boswell K; Ewenstein BM
    Haemophilia; 2009 Sep; 15(5):1083-9. PubMed ID: 19456876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of recombinant factor VIIa in the perioperative period.
    Levi M
    Hamostaseologie; 2009 Jan; 29(1):68-70. PubMed ID: 19151850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.
    Salaj P; Penka M; Smejkal P; Geierova V; Ovesná P; Brabec P; Cetkovsky P; Kubes R; Mesterton J; Lindgren P
    Thromb Res; 2012 May; 129(5):e233-7. PubMed ID: 22386136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind, randomized, controlled study to explore the efficacy of rFVIIa on intraoperative blood loss and mortality in patients with severe acute pancreatitis.
    Lu J; Liao LM; Geng YX; Wang X; Tong ZH; Ke L; Li WQ; Li N; Li JS
    Thromb Res; 2014 Apr; 133(4):574-8. PubMed ID: 24457144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Early, Low-Dose Factor VIIa on Subsequent Transfusions and Length of Stay in Cardiac Surgery.
    Sutherland L; Houchin A; Wang T; Wang S; Moitra V; Sharma A; Zorn T; Flynn BC
    J Cardiothorac Vasc Anesth; 2022 Jan; 36(1):147-154. PubMed ID: 34103218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of recombinant factor VIIa in warfarin patients with traumatic brain injury: a retrospective case-control study.
    DeLoughery EP; Lenfesty B; DeLoughery TG
    Blood Coagul Fibrinolysis; 2013 Apr; 24(3):317-20. PubMed ID: 23429251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic evaluation of rFVIIa high initial dose compared to rFVIIa standard initial dose in patients with haemophilia with inhibitors using the Czech HemoRec registry.
    Salaj P; Kubes R; Cetkovsky P; Capova I; Penka M; Ovesná P; Mesterton J; Lindgren P
    Thromb Res; 2014 Feb; 133(2):162-7. PubMed ID: 24321420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation.
    Lodge JP; Jonas S; Jones RM; Olausson M; Mir-Pallardo J; Soefelt S; Garcia-Valdecasas JC; McAlister V; Mirza DF;
    Liver Transpl; 2005 Aug; 11(8):973-9. PubMed ID: 16035095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of acidosis and hypothermia on blood transfusion requirements following factor VII administration.
    Hall K; Forrest P; Sawyer C
    Anaesth Intensive Care; 2007 Aug; 35(4):494-7. PubMed ID: 18020065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.